{"id":"W4406486966","doi":"10.1080/14796694.2024.2440277","title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Alberta; Precision Nanosystems (Canada); University of Ottawa; University of British Columbia; Ottawa Hospital; Queen's University","funders":"National Health and Medical Research Council; Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Hormone therapy; Cancer; Androgen receptor; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004295322,0.0008430508,0.002276001,0.0005652816,0.0002868836,0.002100394,0.0007372898,0.001392398,0.01476561],"category_scores_gemma":[0.008224444,0.0003365859,0.003448209,0.0009366134,0.000229883,0.001125858,0.000389276,0.002768121,0.002352493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001076705,"about_ca_system_score_gemma":0.001287994,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002099105,"about_ca_topic_score_gemma":0.005324258,"domain_scores_codex":[0.9978726,0.001313553,0.0003073678,0.00008535401,0.0003358259,0.00008533928],"domain_scores_gemma":[0.9966522,0.001489716,0.0009812696,0.0001029253,0.0005435921,0.00023044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06019291,0.0006134188,0.001336385,0.05478282,0.007647623,0.0002309502,0.0001169577,0.00127601,0.001776259,0.001868208,0.4276307,0.4425278],"study_design_scores_gemma":[0.1688814,0.02451089,0.02199607,0.04543554,0.02609004,0.0007649485,0.0002876758,0.001388776,0.001892478,0.00489687,0.7035567,0.0002984985],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.02647398,0.7731999,0.002466233,0.08692979,0.01732885,0.004596395,0.03173126,0.0005513502,0.0567223],"genre_scores_gemma":[0.172781,0.5628669,0.01132847,0.141473,0.02180075,0.008214737,0.02931651,0.0004448837,0.05177384],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01476561,"threshold_uncertainty_score":0.04939592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01844197879047274,"score_gpt":0.3590594813406267,"score_spread":0.3406175025501539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}